γ,γ'-tetramethylhexadecanedioic acid | 210557-73-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: γ,γ'-tetramethylhexadecanedioic acid
• 英文别名: 4.4,13,13-Tetramethylhexadecanedioic Acid；4,4,13,13-Tetramethylhexadecanedioic acid
• CAS: 210557-73-6
• 化学式: C₂₀H₃₈O₄
• 分子量: 342.519
• InChiKey: MKZKFKFOTOSWSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  24
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
  申请人：——

  公开号：US20020049345A1

  公开（公告）日：2002-04-25

  The invention relates to carboxylic acids and derivatives thereof and pharmaceutical compound containing them. The active compounds are represented by the formula compound represented by formula I, wherin R 1 -R 4 each independently represents an unsubstituted or substituted hydrocarbyl or heterocyclyl radical, Q represents a diradical consisting of a linear chain of 11 to 18 carbon atoms, one or more of which may be replaced by heteroatoms, said chain being optionally substituted by inert substituents and one or more of said carbon or heteroatom chain members optionally forming part of a ring structure, and where one or both of de carboxyl groups can be substituted by an in vitro hydrolyzable physiologically acceptable substituent; with the proviso that: compounds wherein R 1 -R 4 each represents CH 3 and Q represents a linear chain of 14 carbons, are excluded; and compounds wherein Q represents a linear chain of carbon atoms one of which is replaced by oxygen or sulfur, are excluded. 1

  本发明涉及羧酸及其衍生物和含有它们的药物化合物。活性化合物由式I表示，其中R1-R4各自独立地表示未取代或取代的烃基或杂环基，Q表示由11到18个碳原子的线性链组成的双原子基团，其中可以有一个或多个被杂原子取代，该链可以被惰性取代基取代，并且该碳或杂原子链的一个或多个成员可以选择地构成环结构，其中一个或两个羧基可以被体外水解的生理可接受的取代基取代；但是具有以下特征：其中R1-R4表示CH3且Q表示14个碳原子的线性链的化合物被排除；以及Q表示碳原子链的一个原子被氧或硫替换的化合物被排除。
• Method of treating osteoarthritis
  申请人：——

  公开号：US20040048910A1

  公开（公告）日：2004-03-11

  This invention relates to combinations, compositions, and methods using or having a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof, as an active component for preventing or treating osteoarthritis, preventing or inhibiting cartilage damage, preventing or treating rheumatoid arthritis, improving joint function, alleviating pain, and the like in a patient in need thereof.

  本发明涉及使用或含有取代的二烷基醚、取代的芳基-烷基醚、取代的二烷基硫醚、取代的二烷基酮或取代的烷基化合物，或其药学上可接受的盐作为活性成分，用于预防或治疗骨关节炎、预防或抑制软骨损伤、预防或治疗类风湿关节炎、改善关节功能、缓解疼痛等方面的组合物、组成物和方法，适用于需要治疗的患者。
• Method of lowering CRP and reducing systemic inflammation
  申请人：——

  公开号：US20040167229A1

  公开（公告）日：2004-08-26

  Disclosed are methods of lowering plasma CRP levels, reducing systemic inflammation, and inhibiting proinflammatory cytokine induced CRP production by administering an effective amount of a substituted dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, substituted-alkyl, or a pharmaceutically acceptable salt of the substituted dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl or a pharmaceutical composition comprising a substituted dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, substituted-alkyl.

  本发明涉及通过给予有效量的取代二烷基醚、取代烷基、取代芳基-烷基、取代二烷基硫醚、取代二烷基酮、取代烷基或其药学上可接受的盐，以及包含取代二烷基醚、取代烷基、取代芳基-烷基、取代二烷基硫醚、取代二烷基酮、取代烷基的药物组合物，来降低血浆CRP水平，减少全身性炎症，并抑制促炎细胞因子诱导的CRP产生的方法。
• Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such
  申请人：Kowala C. Mark

  公开号：US20050004196A1

  公开（公告）日：2005-01-06

  Disclosed herein are pharmaceutical compositions including a dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, substituted-alkyl, or a pharmaceutically acceptable salt of said dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl, and a selective cyclooxygenase-2 (COX-2) inhibitor, or a pharmaceutically acceptable salt of said selective COX-2 inhibitor. Also disclosed are methods of using such pharmaceutical compositions for the treatment of inflammation and inflammation-associated diseases, inflammation and inflammation-associated disorders mediated by proinflammatory cytokines, and proinflammatory cytokine induced CRP production.

  本文公开了药物组合物，包括二烷基醚、取代的烷基、取代的芳基烷基、取代的二烷基硫醚、取代的二烷基酮、取代的烷基或所述二烷基醚、取代的烷基、取代的芳基烷基、取代的二烷基硫醚、取代的二烷基酮或取代的烷基的药学上可接受的盐，以及选择性环氧化酶-2（COX-2）抑制剂或所述选择性COX-2抑制剂的药学上可接受的盐。还公开了使用此类药物组合物治疗炎症和炎症相关疾病、由促炎细胞因子介导的炎症和炎症相关疾病以及促炎细胞因子诱导的 CRP 生成的方法。
• Methods for treating inflammation and inflammation-associated diseases with a statin and ether
  申请人：Ghazzi Maha

  公开号：US20050026979A1

  公开（公告）日：2005-02-03

  Disclosed herein are methods for treating and preventing inflammation and inflammation-associated diseases by co-administering to a patient in need thereof a dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, substituted-alkyl, or a pharmaceutically acceptable salt of said dialkyl ether, substituted alkyl, substituted alkyl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl, and a statin, or a pharmaceutically acceptable salt of said statin.

  本文公开了治疗和预防炎症和炎症相关疾病的方法，即向有需要的患者联合施用二烷基醚、取代的烷基、取代的芳基-烷基、取代的二烷基硫醚、取代的二烷基酮、取代的烷基或所述二烷基醚、取代的烷基、取代的烷基-烷基、取代的二烷基硫醚、取代的二烷基酮或取代的烷基的药学上可接受的盐，以及他汀类药物或所述他汀类药物的药学上可接受的盐。